- Home
- ENTX vs IOR Comparison
ENTX vs IOR Comparison
Compare ENTX & IOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- IOR
- Stock Information
- Founded
- ENTX 2010
- IOR 1984
- Country
- ENTX Israel
- IOR United States
- Employees
- ENTX 21
- IOR N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- IOR Real Estate Investment Trusts
- Sector
- ENTX Health Care
- IOR Real Estate
- Exchange
- ENTX Nasdaq
- IOR Nasdaq
- Market Cap
- ENTX 91.3M
- IOR 72.8M
- IPO Year
- ENTX 2018
- IOR N/A
- Fundamental
- Price
- ENTX $2.00
- IOR $18.68
- Analyst Decision
- ENTX Strong Buy
- IOR
- Analyst Count
- ENTX 1
- IOR 0
- Target Price
- ENTX $10.00
- IOR N/A
- AVG Volume (30 Days)
- ENTX 294.0K
- IOR 311.0
- Earning Date
- ENTX 08-08-2025
- IOR 08-07-2025
- Dividend Yield
- ENTX N/A
- IOR N/A
- EPS Growth
- ENTX N/A
- IOR N/A
- EPS
- ENTX N/A
- IOR 1.06
- Revenue
- ENTX $166,000.00
- IOR N/A
- Revenue This Year
- ENTX N/A
- IOR N/A
- Revenue Next Year
- ENTX N/A
- IOR N/A
- P/E Ratio
- ENTX N/A
- IOR $17.69
- Revenue Growth
- ENTX 191.23
- IOR N/A
- 52 Week Low
- ENTX $1.50
- IOR $16.01
- 52 Week High
- ENTX $2.79
- IOR $19.69
- Technical
- Relative Strength Index (RSI)
- ENTX 54.00
- IOR 51.14
- Support Level
- ENTX $1.87
- IOR $18.02
- Resistance Level
- ENTX $2.14
- IOR $18.89
- Average True Range (ATR)
- ENTX 0.10
- IOR 0.18
- MACD
- ENTX 0.00
- IOR -0.01
- Stochastic Oscillator
- ENTX 60.00
- IOR 79.38
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.